Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 Plus Weekly Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT04055649Phase 2Recruiting
- Start
- Jan 2020
- Primary completion
- May 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dordaviprone in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC). Primary endpoints: Incidence of treatment related adverse events at 28 days, Incidence of dose limiting toxicities at 28 days and 2 more. Started Jan 2020; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04055649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055649.